Boston Partners Raises Stock Holdings in Evolent Health, Inc. (NYSE:EVH)

Boston Partners grew its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 92.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,444,006 shares of the technology company's stock after buying an additional 1,171,304 shares during the period. Boston Partners owned approximately 2.10% of Evolent Health worth $27,097,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Foundry Partners LLC bought a new position in Evolent Health during the third quarter worth $10,042,000. Salem Investment Counselors Inc. raised its holdings in shares of Evolent Health by 53.0% during the fourth quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company's stock valued at $3,939,000 after purchasing an additional 121,369 shares during the period. Nordea Investment Management AB boosted its position in shares of Evolent Health by 7.0% during the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company's stock worth $1,469,000 after purchasing an additional 8,552 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in Evolent Health by 90.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock valued at $9,036,000 after buying an additional 380,790 shares in the last quarter. Finally, Bellevue Group AG increased its position in Evolent Health by 59.9% in the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company's stock valued at $75,509,000 after buying an additional 1,000,215 shares in the last quarter.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have commented on EVH shares. Oppenheimer reduced their price objective on Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, January 24th. UBS Group decreased their price target on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, January 16th. Piper Sandler reaffirmed an "overweight" rating and issued a $16.00 price objective (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. JMP Securities reissued a "market outperform" rating and set a $12.00 target price on shares of Evolent Health in a research report on Friday, February 14th. Finally, BTIG Research lowered their target price on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Evolent Health has an average rating of "Buy" and an average price target of $17.71.

Insider Activity at Evolent Health

In related news, Director Brendan B. Springstubb bought 5,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the purchase, the director now owns 11,842 shares of the company's stock, valued at approximately $103,617.50. The trade was a 73.08 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Daniel Joseph Mccarthy purchased 11,040 shares of Evolent Health stock in a transaction dated Thursday, March 6th. The stock was bought at an average price of $9.01 per share, with a total value of $99,470.40. Following the completion of the purchase, the president now directly owns 389,004 shares of the company's stock, valued at approximately $3,504,926.04. This trade represents a 2.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 74,000 shares of company stock worth $666,315 over the last 90 days. 1.60% of the stock is owned by company insiders.

Evolent Health Price Performance

Shares of NYSE EVH traded up $0.11 during trading hours on Monday, reaching $9.69. 1,430,150 shares of the stock traded hands, compared to its average volume of 2,117,880. The company has a market capitalization of $1.13 billion, a P/E ratio of -11.81 and a beta of 1.49. The company's 50-day simple moving average is $9.93 and its two-hundred day simple moving average is $16.06. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). The company had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. Equities research analysts forecast that Evolent Health, Inc. will post 0.08 EPS for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.